Allergic contact dermatitis from topical doxepin: Food and Drug Administration's postmarketing surveillance experience

Renan A Bonnel; Lois La Grenade; Claudia B Karwoski; Julie G Beitz

doi:10.1067/mjd.2003.46

Allergic contact dermatitis from topical doxepin: Food and Drug Administration's postmarketing surveillance experience

J Am Acad Dermatol. 2003 Feb;48(2):294-6. doi: 10.1067/mjd.2003.46.

Authors

Renan A Bonnel¹, Lois La Grenade, Claudia B Karwoski, Julie G Beitz

Affiliation

¹ Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, Room 15B-23, HFD-430, Rockville, MD 20857, USA.

PMID: 12582408
DOI: 10.1067/mjd.2003.46

Abstract

A total of 26 postmarketing cases of allergic contact dermatitis to doxepin 5% cream were reported to the Food and Drug Administration. Our findings suggest that allergic contact dermatitis was more common when treatment duration exceeded the recommended 8 days. Allergic contact dermatitis to doxepin cream should be considered in patients whose condition fails to improve or worsens with doxepin use.

Publication types

Case Reports

MeSH terms

Administration, Topical
Adult
Antipruritics / administration & dosage
Antipruritics / adverse effects*
Dermatitis, Allergic Contact / etiology*
Doxepin / administration & dosage
Doxepin / adverse effects*
Female
Humans
Male
Middle Aged
Product Surveillance, Postmarketing*

Substances

Antipruritics
Doxepin